Clinical Trials Browser

Phase 2 × anlotinib × Tumor-Agnostic × Clear all

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Phase 2 Completed

Neoplasm Metastasis

NCT01878448 2019-05-22

ALTN/STS

Phase 2 Completed

Neoplasms

NCT01874873 2019-05-21

ALTN/MTC

Phase 2 Completed

Neoplasms